sun pharmaceutical

Sabit4 haber1 kaynakSon güncelleme: 27.04.2026

İlgili Etiketlerorganon acquisition pharmaceuticals merger india united states women's health biosimilars

Son Haberler

Business·27.04.2026AI özeti

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Deal

Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co for $11.75 billion in an all-cash deal. The acquisition values Organon at $14 per share and will help lift the Indian generics major into the top 25 global pharmaceutical companies with combined revenue of $12.4 billion. Organon, spun off from Merck in 2021, specializes in women's health and biosimilars with over 70 products sold across 140 countries. The deal will increase Sun Pharma's innovative medicine segment contribution from 20% to 27% of total sales.

Sun Pharma shares jump 5% as India's largest drugmaker to buy U.S. firm Organon in $11.75 billion deal

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.

CNBC

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Pharma Deal

Acil

Business·27.04.2026AI özeti

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Pharma Deal

Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co for $11.75 billion in an all-cash deal. The Indian drugmaker will pay $14 per share for all outstanding Organon shares, which was spun off from Merck in 2021. The acquisition will create a pharmaceutical giant with $12.4 billion in revenue, lifting Sun Pharma into the top 25 global pharmaceutical companies. Organon specializes in women's health and biosimilars with over 70 products sold across 140 countries.

Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.

CNBC